Volker Arndt
Has grant
Group leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Cancer survivorship and quality of life in long-term survivors of colorectal, breast and prostate cancer
Open Date: 2008-10-01
Close Date: 2012-06-01
Articles (22)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Purpose This systematic review aims to summarize the associations between combined healthy lifestyles and psychosocial outcomes (health-related quality of life (HRQOL), depression, anxiety, psychological distress (PD), and posttraumatic stress disorder (PTSD)) among cancer survivors. Methods PubMed, Web of Science, Cochrane Library, and EMBASE were searched for observational and interventional studies examining healthy lifestyle scores (HLS, calculated by a combination of at least three lifestyles) and psychosocial outcomes among cancer survivors from inception to April 2024. A minimum of two studies with the same study design were pooled using random effects models. Results Twenty-one studies (44,812 survivors) were included. Of all studies, 16 of which were included in meta-analysis. The pooling of cross-sectional evidence shows significant association between HLS and overall, physical, and psychosocial HRQOL. Significance was only observed for overall and physical HRQOL but not for psychosocial HRQOL in cohort studies. The estimations and 95% confidence interval (CI) with 1-point increase in HLS were 1.47 (0.83–2.12) and 1.42 (0.19–2.65) for overall and physical HRQOL, respectively. The evidence from interventional studies also indicated that interventions on multiple lifestyles have positive effects on the physical but not psychosocial HRQOL. Despite the limited number of studies, significant associations were found between HLS and depression, anxiety, PD, and PTSD. Conclusions Although evidence is limited, we found that the combination of multiple healthier lifestyles is associated with better psychosocial outcomes in cancer survivors. Implications for cancer survivors This review underscores the potential for adhering to multiple healthy lifestyles to improve psychosocial outcomes and enhance HRQOL for cancer survivors.
Year:
2026
Year:
2026
With improved survival, noncancer causes of death have become increasingly relevant in cancer care. Excess noncancer mortality may reflect treatment-related toxicity, comorbidities, shared risk factors, and psychologic distress. This scoping review aimed to map the population-based evidence on the causes of death in patients with cancer and identify research gaps. PubMed, Web of Science, Cochrane Library, EMBASE, and Scopus were searched until April 2025. A total of 203 population-based studies using standardized mortality ratios (SMR) to compare cause-specific mortality among patients with cancer with that of the general population were included. Noncancer mortality was consistently elevated among patients with cancer [median SMR 1.60; interquartile range (IQR) 1.24–2.51], especially during the first year after diagnosis (3.42; 1.45–6.92), and remained higher over 10 years after diagnosis (1.51; 1.08–5.49). Younger patients and those with advanced-stage cancers demonstrated higher noncancer mortality. Among specific causes, cardiovascular disease (1.37; 1.09–2.34), suicide (1.73; 1.32–2.77), stroke (1.36; 0.98–2.17), infectious diseases in general (2.20; 1.35–4.16), septicemia (2.84; 1.64–5.47), and pneumonia/influenza (1.57; 1.08–2.69) were consistently elevated. Patients with cancer have demonstrated substantial noncancer mortality. These findings identify priority areas for targeted prevention and further investigation into cause-specific mortality patterns beyond cancer-related deaths to improve outcomes.
Year:
2026
Prostate cancer accounts for the largest group of cancer survivors in men. Hormone therapy is essential, especially in advanced disease. While its short-term effects are well studied, research into the long-term effects on health-related quality of life (HRQOL) remains limited. Therefore, this review aims to synthesize and identify key gaps in the literature on HRQOL and symptom burden in long-term prostate cancer survivors who underwent hormone therapy. After searching four databases until 15 April 2025, we identified 14 observational studies that reported on general and prostate cancer-specific HRQOL in prostate cancer survivors ≥ 5 years post-diagnosis. Survivors who underwent hormone therapy reported worse global health status and physical, emotional, and social functioning compared to those treated with local therapies like prostatectomy or radiation. These survivors also experienced greater symptom burdens, alongside worse vitality and mental health. Prostate cancer-specific issues, such as bowel and urinary bother and sexual dysfunction, were also more pronounced in hormone therapy recipients. Nevertheless, outcomes beyond 15 years remain under-researched. The findings of this review highlight the importance of discussing long-term HRQOL compromises with patients who consider hormone therapy. However, they warrant cautious interpretation, particularly due to limited details on hormone therapy regimens and inadequate control for stage.
Year:
2026
PurposeThe European Oncology Quality of Life (EUonQoL) project aims to develop a questionnaire toolkit (EUonQoL-Kit) to assess the quality of life (QoL) of cancer patients and survivors across Europe.MethodsThe EUonQoL-Kit development used mixed-methods and a co-design approach. Data was collected in six countries (Denmark, France, Germany, Italy, Netherlands and UK). The target populations were patients in active treatment (A), survivors (B) and patients requiring palliative care (C). A review of existing QoL theoretical models produced an initial EUonQoL conceptual framework. Semi-structured interviews and a Delphi survey evaluated/modified the framework. Existing validated items were used to construct the toolkit, including Computer Adaptive Testing (CAT), where available. A usability study evaluated EUonQoL-Kit.v1. Data triangulation and consensus methodology guided EUonQoL-Kit.v2.ResultsThe initial conceptual framework covered four multi-dimensional domains: physical, social and overall health, and psychological wellbeing. The interviews and Delphi survey included 75 and 155 participants, respectively. The domain ‘healthcare experience’ was identified and included in the framework. EUonQoL-Kit.v1 resulted in three static questionnaires, one for each target population (n items- A=75; B=67; C=79). Following usability testing with 53 participants, EUonQoL-Kit.v2 was produced via a multi-stakeholder consensus development panel, creating a shortened version (n items- A=50; B=50; C=44). Dynamic versions of these questionnaires were developed using the EORTC CAT Core system.ConclusionsEUonQoL-Kit is a novel toolkit developed to assess QoL across the cancer continuum and inform health policy within Europe. Its psychometric properties are currently being evaluated using data collected on more than 4200 patients across 32 countries.
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (66)
Emiel J. Krahmer
The Netherlands Cancer Institute
Li Hsu
Fred Hutchinson Cancer Research Center
Polly Newcomb
University of Washington
Sven Voigtländer
Senior Researcher
University Medical Center of the Johannes Gutenberg University Mainz
Galina Velikova
-
Marc Gunter
International Agency for Research on Cancer
Alice Nennecke
Head
-
Tabitha Harrison
Fred Hutchinson Cancer Research Center
Konstantinos K. Tsilidis
-
Sara Alfieri
Fondazione IRCCS Istituto Nazionale dei Tumori
Mogens Grønvold
Københavns Universitet
Victor Moreno
Professor
University of Barcelona
Marina Evangelou
Senior Lecturer in Statistics
Imperial College London
Fränzel J.B. van Duijnhoven
Wageningen University & Research
Luana Caselli
Fondazione IRCCS Istituto Nazionale dei Tumori
Susanna Larsson
Professor at Karolinska Institutet
Karolinska Institutet
Juan Pablo Lewinger
Associate Professor
University of Southern California
SAM Gernaat
Universitair Medisch Centrum Utrecht
Bernhard Holzner
Prof
Medical University of Innsbruck
David Drew
Assistant Professor of Medicine
Massachusetts General Hospital
Ulrike Peters
Fred Hutchinson Cancer Research Center
Matthew Devall
Assistant Professor
University of Virginia
Sophia Harlid
Umea University
Eric Kawaguchi
Assistant Professor
University of Southern California
Julie R Palmer
Boston University School of Medicine
Meeke Hoedjes
Tilburg University
Elizabeth Platz
Professor
Johns Hopkins University
Mariana C. Stern
Professor
University of Southern California
Augusto Caraceni
Professore associato
Università degli Studi di Torino
Tim Bishop
University of Leeds
Stéphane Bézieau
Université de Nantes
Virginia Díez-Obrero
Vrije Universiteit Amsterdam
Hongmei Nan
Professor
University of Indianapolis
Emmanouil Bouras
Research associate
Imperial College London
Alicja Wolk
Professor of Nutritional Epidemiology
Karolinska Institutet
Anna H. Wu
Professor
University of Southern California
John Potter
Professor
University of Washington
Bethany Van Guelpen
Umea University
Li Li
University of Virginia
Andrea Gsur
Medical University of Vienna
Helle Pappot
University of Copenhagen
Loic Le Marchand
Professor
University of Hawaii
Edward A. Ruiz-Narváez
Associate Professor
University of Michigan School of Public Health
Elom K Aglago
Imperial College London
Christian H. Brandts
Professor & Director
Goethe University Frankfurt
Claudio Lombardo
Università degli Studi di Bologna Dipartimento di Fisica e Astronomia
David Conti
Professor
Colorado School of Public Health
Cinzia Brunelli
Fondazione IRCCS Istituto Nazionale dei Tumori
W. James Gauderman
professor
University of Southern California
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Graham Casey
University of Virginia
Catherine Tangen
Fred Hutchinson Cancer Research Center
Kala Visvanathan
Professor
Johns Hopkins University
Alexandra Gilbert
University of Leeds
Daniel D. Buchanan
Senior Research Fellow
University of Melbourne
Montserrat Ferrer
Associate lecturer
Universitat Pompeu Fabra
Stephen Gruber
Professor
City Of Hope National Medical Center
Leslye Rojas-Concha
Senior researcher and project leader
Københavns Universitet
Anshul Kundaje
Associate Professor
Stanford University
Mark Jenkins
University of Melbourne
Peter T. Campbell
Professor
Albert Einstein College of Medicine
Graham Giles
Head of Research
-
Michael Hoffmeister
Professor of Epidemiology, Group leader, Deputy divison head
German Cancer Research Center (DKFZ)
Elizabeth Barry
Associate Professor
Dartmouth College Geisel School of Medicine
Pavel Vodička
senior researcher
Charles University
Jennifer Ose
Professorin (W2)
Hochschule Hannover
Make your next move.
Prepare your application
Review drafts before you send them.